November MIMS update

Some recent changes to medicines listings, including new products, presentations, indications, contraindications and safety changes New products Ciltacabtagene autoleucel (Carvykti) is a B cell maturation antigen (BCMA)-directed, genetically modified autologous T cell immunotherapy, which involves reprogramming a patient’s own T cells with a transgene encoding a chimeric antigen receptor (CAR) that identifies and eliminates cells that